AMCP submits letter to Connecticut Senate General Law Committee on Senate Bill 197 regarding Interchangeable Biologic Products
The Academy of Managed Care Pharmacy (AMCP) is writing to express concerns with specific provisions of Substitute Bill No.7118 regarding the regulation of biological products and the substitution of interchangeable biological products when dispensed by pharmacists. We strongly support the language in the Substitute Bill that allows a pharmacist to substitute an FDA approved “interchangeable biological product”. That language is consistent with the Biologics Competition and Innovation Act (BPCIA) definition of “interchangeable biologic product” which allows a pharmacist to substitute an interchangeable biologic product without the intervention of the health care provider who prescribed the “reference product”. However, we oppose the language that defines an interchangeable biological product as therapeutically equivalent and imposes administrative requirements to dispense an interchangeable biological product that are different from existing requirements for all other classes of medications. We also are concerned about enacting requirements prior to the FDA finalizing guidance on interchangeable biological products.
Featured News & Resources
See Full CalendarHBCU Travel Awards for AMCP25
Mid-South AMCP Day of Education 2025
Southwest AMCP Annual Day of Education 2025
Upcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.